PHILADELPHIA, July 17, 2020: Morgan Lewis represented Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, in an agreement with a fund affiliated with institutional investors providing for a private placement. Morgan Lewis previously counseled Idera on an April 2020 private placement.
Idera’s development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also focuses on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Morgan Lewis partners Joanne Soslow, Richard Aldridge, and David Schwartz, senior attorney Sally Liao, and associates Richard Umbrecht and Brittany Leon represented Idera.